Tandegyl is an H1 receptor antagonist. It belongs to the benzhydryl ether group of antihistamines.
Tandegyl inhibits selectively the histamine receptors of the H1 type and reduces capillary permeability.
Tandegyl exerts a potent antihistaminic and antipruritic effect with a rapid onset and long duration of action up to 12 hours.
After oral administration, Tandegyl (Clemastine) is almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are attained within 2 to 4 hours. The antihistaminic activity of the drug reaches its peak after 5 to 7 hours; Tandegyl usually persists for 10 to 12 hours, and in some cases, for up to 24 hours.
Plasma protein binding of Tandegyl amounts to 95% elimination from plasma occurs biphasically , with half life of 3.6 ± 0.9 hours and 37 ± 16 hours. Clemestine undergoes extensive metabolism in the liver. The major route of metabolite excretion (45% to 65%) is through the kidneys into the urine, where only trace amount of the parent compound are found. In lactating women, small amount of the drug may pass into breast milk.
Oral dosage form:
Known hypersensitivity to Tandegyl or other antihistamines of similar chemical structure.
Tandegyl should not be given to children under 1 year of age